News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product will be marketed by Dr. Reddy's
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
